Ex-Novo Nordisk director Martin Olin leads newly-formed Swarm

Swarm Oncology, a biotech developing novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, has emerged from stealth mode and announced the appointment of Martin Olin as chief executive.

The UK company’s platform to generate novel T cell therapies addresses a significant unmet need in solid cancers, with more than 82% of patients with advanced metastatic cancer dying from their disease.  

This Swarm-T platform uses immune system priming with proprietary ex vivo cell processing to generate unprecedented, large numbers of T cells with desired phenotypes to home, infiltrate and kill cancer cells.